Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy.

Chih-Chung ChengHung-Chieh YehPei-Wen SuChien-Lin HoSheng-Chi Chang

Published in: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2024)

Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.

Keyphrases

chronic kidney disease
patients undergoing
risk factors
end stage renal disease
primary care
high intensity
palliative care
physical activity
squamous cell carcinoma
emergency department
radiation therapy